MedDataX Logo

Trial Outcomes & Findings for A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (NCT NCT02561962)

NCT ID: NCT02561962

Last Updated: 2024-02-01

Results Overview

Adverse events, including DLTs, were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT was considered as any of the below, if judged by the investigator to be possibly related to AMG 224: Hematological: * Grade 4 neutropenia lasting \> 7 days * Grade 3 or 4 neutropenia with fever \> 38.5°C * Grade 3 thrombocytopenia with ≥ Grade 2 hemorrhage * Grade 4 thrombocytopenia lasting \> 7 days * Grade 3 anemia with symptoms or required intervention * Grade 4 anemia * Lymphopenia is not considered a DLT Non-hematological: * ≥ Grade 3 nausea, vomiting or diarrhea persisting \> 3 days despite optimal medical support * Grade 3 fatigue persisting \> 7 days * ≥ Grade 3 acute kidney injury lasting \> 3 days * Elevation of aspartate aminotransferase or alanine aminotransferase \>3x to \>8x upper limit of normal (ULT) dependent on criteria * Total bilirubin \> 3x ULN Participants meeting the criteria for Hy's Law case were considered to have a DLT.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

42 participants

Primary outcome timeframe

Day 1 to Day 28

Results posted on

2024-02-01

Participant Flow

A total of 42 participants were enrolled in the study at 4 research centers in Australia and the United States from 20 November 2015 to 21 April 2022. Primary completion date: 30 Nov 2018.

Doses of AMG 224 in dose exploration part range from lowest in Dose A (30mg) up to highest in Dose G (250mg). Specific doses are blinded due to the protection of propriety information.

Participant milestones

Participant milestones
Measure
Dose Exploration: AMG 224 Dose A
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Overall Study
STARTED
3
3
3
3
6
6
5
11
2
Overall Study
Received Treatment
3
3
3
3
6
6
5
9
2
Overall Study
COMPLETED
2
3
3
3
4
3
3
7
2
Overall Study
NOT COMPLETED
1
0
0
0
2
3
2
4
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Dose Exploration: AMG 224 Dose A
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Overall Study
Withdrawal by Subject
1
0
0
0
1
1
2
1
0
Overall Study
Decision by sponsor
0
0
0
0
1
1
0
3
0
Overall Study
Lost to Follow-up
0
0
0
0
0
1
0
0
0

Baseline Characteristics

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Total
n=40 Participants
Total of all reporting groups
Age, Continuous
63.3 years
STANDARD_DEVIATION 7.0 • n=5 Participants
63.7 years
STANDARD_DEVIATION 3.8 • n=7 Participants
64.3 years
STANDARD_DEVIATION 11.2 • n=5 Participants
70.7 years
STANDARD_DEVIATION 4.0 • n=4 Participants
60.5 years
STANDARD_DEVIATION 7.1 • n=21 Participants
65.0 years
STANDARD_DEVIATION 5.7 • n=10 Participants
58.2 years
STANDARD_DEVIATION 6.0 • n=115 Participants
71.3 years
STANDARD_DEVIATION 8.7 • n=24 Participants
53.0 years
STANDARD_DEVIATION 9.9 • n=42 Participants
64.5 years
STANDARD_DEVIATION 8.4 • n=42 Participants
Sex: Female, Male
Female
1 Participants
n=5 Participants
2 Participants
n=7 Participants
1 Participants
n=5 Participants
1 Participants
n=4 Participants
3 Participants
n=21 Participants
4 Participants
n=10 Participants
4 Participants
n=115 Participants
4 Participants
n=24 Participants
1 Participants
n=42 Participants
21 Participants
n=42 Participants
Sex: Female, Male
Male
2 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
2 Participants
n=4 Participants
3 Participants
n=21 Participants
2 Participants
n=10 Participants
1 Participants
n=115 Participants
5 Participants
n=24 Participants
1 Participants
n=42 Participants
19 Participants
n=42 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
2 Participants
n=21 Participants
2 Participants
n=10 Participants
2 Participants
n=115 Participants
1 Participants
n=24 Participants
1 Participants
n=42 Participants
8 Participants
n=42 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants
n=5 Participants
3 Participants
n=7 Participants
3 Participants
n=5 Participants
3 Participants
n=4 Participants
4 Participants
n=21 Participants
4 Participants
n=10 Participants
3 Participants
n=115 Participants
8 Participants
n=24 Participants
1 Participants
n=42 Participants
32 Participants
n=42 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
0 Participants
n=10 Participants
0 Participants
n=115 Participants
0 Participants
n=24 Participants
0 Participants
n=42 Participants
0 Participants
n=42 Participants
Race/Ethnicity, Customized
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
0 Participants
n=10 Participants
0 Participants
n=115 Participants
0 Participants
n=24 Participants
0 Participants
n=42 Participants
1 Participants
n=42 Participants
Race/Ethnicity, Customized
Black (or African American)
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
1 Participants
n=21 Participants
2 Participants
n=10 Participants
1 Participants
n=115 Participants
2 Participants
n=24 Participants
0 Participants
n=42 Participants
6 Participants
n=42 Participants
Race/Ethnicity, Customized
White
0 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
3 Participants
n=4 Participants
4 Participants
n=21 Participants
3 Participants
n=10 Participants
3 Participants
n=115 Participants
7 Participants
n=24 Participants
2 Participants
n=42 Participants
25 Participants
n=42 Participants
Race/Ethnicity, Customized
Other
3 Participants
n=5 Participants
2 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
1 Participants
n=21 Participants
1 Participants
n=10 Participants
1 Participants
n=115 Participants
0 Participants
n=24 Participants
0 Participants
n=42 Participants
8 Participants
n=42 Participants

PRIMARY outcome

Timeframe: Day 1 to Day 28

Population: DLT analysis set: all participants who are DLT evaluable. A participant was not DLT-evaluable if the participant discontinued treatment for any reason other than a DLT prior to completing the first 28 days of AMG 224 treatment or did not receive 2 doses of AMG 224 during the 28-day DLT window.

Adverse events, including DLTs, were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT was considered as any of the below, if judged by the investigator to be possibly related to AMG 224: Hematological: * Grade 4 neutropenia lasting \> 7 days * Grade 3 or 4 neutropenia with fever \> 38.5°C * Grade 3 thrombocytopenia with ≥ Grade 2 hemorrhage * Grade 4 thrombocytopenia lasting \> 7 days * Grade 3 anemia with symptoms or required intervention * Grade 4 anemia * Lymphopenia is not considered a DLT Non-hematological: * ≥ Grade 3 nausea, vomiting or diarrhea persisting \> 3 days despite optimal medical support * Grade 3 fatigue persisting \> 7 days * ≥ Grade 3 acute kidney injury lasting \> 3 days * Elevation of aspartate aminotransferase or alanine aminotransferase \>3x to \>8x upper limit of normal (ULT) dependent on criteria * Total bilirubin \> 3x ULN Participants meeting the criteria for Hy's Law case were considered to have a DLT.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=3 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=4 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=8 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=1 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
1 Participants
3 Participants
0 Participants
0 Participants

PRIMARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of Cycle 4, where each cycle is 3 weeks; up to 12 weeks.

Population: Safety analysis set: all participants that are enrolled and received at least 1 dose of AMG 224.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. TEAEs were any AE that occurred after receiving at least 1 dose of treatment. Treatment-related TEAEs were those considered related to study treatment by the investigator. Any clinically significant changes in ECGs, vital signs, physical examination with a neurologic assessment and clinical laboratory tests were recorded as TEAEs.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
TEAE
3 Participants
3 Participants
3 Participants
3 Participants
6 Participants
6 Participants
5 Participants
9 Participants
2 Participants
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Treatment-related TEAE
3 Participants
3 Participants
3 Participants
3 Participants
5 Participants
5 Participants
5 Participants
7 Participants
1 Participants

SECONDARY outcome

Timeframe: AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, end of infusion (EOI), 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)

Population: The pharmacokinetic (PK) parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.

Cmax of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-\[N-maleimidomethyl\] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=5 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=10 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 1
11.4 µg/mL
Interval 5.99 to 14.3
22.0 µg/mL
Interval 16.4 to 28.9
25.3 µg/mL
Interval 20.0 to 31.2
32.9 µg/mL
Interval 19.8 to 42.9
37.5 µg/mL
Interval 6.32 to 67.7
54.2 µg/mL
Interval 45.1 to 74.4
61.9 µg/mL
Interval 47.1 to 75.5
55.8 µg/mL
Interval 39.9 to 80.9
—
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 2
11.5 µg/mL
Interval 8.26 to 15.4
29.3 µg/mL
Interval 20.6 to 44.6
31.0 µg/mL
Interval 26.4 to 39.0
38.5 µg/mL
Interval 24.0 to 51.5
40.1 µg/mL
Interval 29.0 to 53.8
60.8 µg/mL
Interval 51.2 to 84.7
78.7 µg/mL
Interval 67.4 to 89.9
73.3 µg/mL
Interval 46.6 to 89.9
—
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 1
11.9 µg/mL
Interval 7.09 to 14.5
23.9 µg/mL
Interval 20.4 to 30.5
25.3 µg/mL
Interval 21.4 to 29.8
34.7 µg/mL
Interval 19.3 to 47.2
40.2 µg/mL
Interval 8.72 to 75.8
52.4 µg/mL
Interval 49.6 to 55.5
67.7 µg/mL
Interval 50.4 to 84.9
52.1 µg/mL
Interval 33.7 to 73.8
—
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 2
11.9 µg/mL
Interval 9.84 to 13.5
34.6 µg/mL
Interval 22.5 to 51.8
33.2 µg/mL
Interval 28.9 to 40.5
41.6 µg/mL
Interval 25.0 to 56.2
45.3 µg/mL
Interval 34.6 to 63.9
63.4 µg/mL
Interval 55.5 to 72.4
79.6 µg/mL
Interval 50.2 to 109.0
62.4 µg/mL
Interval 39.0 to 77.2
—
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
DM1 after Cycle 1
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.000312 µg/mL
Interval 0.0 to 0.000501
0.000549 µg/mL
Interval 0.000445 to 0.000693
0.00131 µg/mL
Interval 0.000568 to 0.0021
0.00141 µg/mL
Interval 0.000967 to 0.00192
0.00155 µg/mL
Interval 0.00123 to 0.00201
0.00149 µg/mL
Interval 0.000924 to 0.0021
—
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
DM1 after Cycle 2
0.00 µg/mL
Interval 0.0 to 0.0
0.000119 µg/mL
Interval 0.0 to 0.000356
0.000414 µg/mL
Interval 0.000297 to 0.00059
0.000654 µg/mL
Interval 0.000423 to 0.000913
0.000872 µg/mL
Interval 0.000658 to 0.00121
0.00172 µg/mL
Interval 0.00141 to 0.00264
0.00161 µg/mL
Interval 0.00151 to 0.0017
0.00177 µg/mL
Interval 0.0014 to 0.00242
—

SECONDARY outcome

Timeframe: AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)

Population: The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.

Cmin of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=5 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=10 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 2
1.51 µg/mL
Interval 0.811 to 1.93
3.06 µg/mL
Interval 2.44 to 4.05
6.71 µg/mL
Interval 5.97 to 7.99
5.91 µg/mL
Interval 3.33 to 10.1
6.64 µg/mL
Interval 1.91 to 12.0
15.2 µg/mL
Interval 5.75 to 20.4
20.0 µg/mL
Interval 3.87 to 36.2
15.9 µg/mL
Interval 4.68 to 27.7
—
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 1
1.45 µg/mL
Interval 0.97 to 1.71
2.81 µg/mL
Interval 2.11 to 4.05
4.54 µg/mL
Interval 3.7 to 5.46
4.40 µg/mL
Interval 1.69 to 8.8
3.51 µg/mL
Interval 2.11 to 6.32
10.5 µg/mL
Interval 5.75 to 18.2
9.29 µg/mL
Interval 3.87 to 14.7
10.6 µg/mL
Interval 3.65 to 16.6
—
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 1
1.70 µg/mL
Interval 1.05 to 2.07
3.91 µg/mL
Interval 2.56 to 5.83
6.69 µg/mL
Interval 5.52 to 8.27
5.50 µg/mL
Interval 2.78 to 9.87
4.86 µg/mL
Interval 2.86 to 8.72
13.5 µg/mL
Interval 8.14 to 17.5
10.9 µg/mL
Interval 3.47 to 18.3
9.47 µg/mL
Interval 3.76 to 15.1
—
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 2
2.25 µg/mL
Interval 1.25 to 2.78
4.62 µg/mL
Interval 3.78 to 5.83
11.9 µg/mL
Interval 10.2 to 14.7
10.1 µg/mL
Interval 4.24 to 19.1
11.3 µg/mL
Interval 3.72 to 21.0
21.8 µg/mL
Interval 8.14 to 33.6
15.4 µg/mL
Interval 3.47 to 27.4
13.1 µg/mL
Interval 4.56 to 23.7
—
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
DM1 after Cycle 1
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.000160 µg/mL
Interval 0.0 to 0.000341
0.000268 µg/mL
Interval 0.0 to 0.000353
0.000206 µg/mL
Interval 0.0 to 0.000408
0.000189 µg/mL
Interval 0.0 to 0.000694
—
Minimum Observed Concentration (Cmin) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
DM1 after Cycle 2
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.00 µg/mL
Interval 0.0 to 0.0
0.000150 µg/mL
Interval 0.0 to 0.0003
0.000468 µg/mL
Interval 0.000443 to 0.000535
0.000254 µg/mL
Interval 0.0 to 0.000507
0.000494 µg/mL
Interval 0.000364 to 0.000796
—

SECONDARY outcome

Timeframe: AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycle 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)

Population: The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated. All participants included in the overall number of participants analyzed contributed data to this endpoint.

AUC from time zero to 3 weeks (AUC(3 weeks)) was determined for AMG 224 conjugated antibody and total anti-BCMA antibody, and AUC from time zero to 96 hours (AUC(0-96hr)) was determined for DM1.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=5 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=4 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=8 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(3weeks): AMG 224 Conjugated Antibody after Cycle 2
2330 h*µg/mL
Interval 1340.0 to 2900.0
3650 h*µg/mL
Interval 3460.0 to 3840.0
6360 h*µg/mL
Interval 5820.0 to 7250.0
7400 h*µg/mL
Interval 4000.0 to 9640.0
7610 h*µg/mL
Interval 4250.0 to 12400.0
14100 h*µg/mL
Interval 13100.0 to 15100.0
23000 h*µg/mL
Interval 23000.0 to 23000.0
15500 h*µg/mL
Interval 10100.0 to 20800.0
—
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(3weeks): AMG 224 Conjugated Antibody after Cycle 1
1850 h*µg/mL
Interval 1240.0 to 2560.0
3450 h*µg/mL
Interval 2870.0 to 4240.0
4520 h*µg/mL
Interval 3910.0 to 4950.0
5260 h*µg/mL
Interval 2750.0 to 7570.0
3710 h*µg/mL
Interval 1590.0 to 4970.0
10400 h*µg/mL
Interval 9040.0 to 14300.0
10500 h*µg/mL
Interval 7060.0 to 14000.0
9690 h*µg/mL
Interval 5620.0 to 14000.0
—
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(3weeks): Total Anti-BCMA Antibody after Cycle 1
1990 h*µg/mL
Interval 1300.0 to 2690.0
3850 h*µg/mL
Interval 3300.0 to 4450.0
5120 h*µg/mL
Interval 4540.0 to 5910.0
5870 h*µg/mL
Interval 3160.0 to 8110.0
4220 h*µg/mL
Interval 2200.0 to 5440.0
11300 h*µg/mL
Interval 10400.0 to 12500.0
11200 h*µg/mL
Interval 6140.0 to 16200.0
8680 h*µg/mL
Interval 6640.0 to 11400.0
—
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(3weeks): Total Anti-BCMA Antibody after Cycle 2
2530 h*µg/mL
Interval 1460.0 to 3310.0
4370 h*µg/mL
Interval 4180.0 to 4560.0
8140 h*µg/mL
Interval 7140.0 to 10100.0
9170 h*µg/mL
Interval 4660.0 to 13200.0
9250 h*µg/mL
Interval 4900.0 to 16100.0
18500 h*µg/mL
Interval 17400.0 to 20500.0
24700 h*µg/mL
Interval 24700.0 to 24700.0
13000 h*µg/mL
Interval 8880.0 to 18600.0
—
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(0-96hr): DM1 after Cycle 1
—
—
—
—
0.0729 h*µg/mL
Interval 0.0729 to 0.0729
0.0487 h*µg/mL
Interval 0.0328 to 0.0597
0.0579 h*µg/mL
Interval 0.0421 to 0.0668
0.0646 h*µg/mL
Interval 0.0426 to 0.0743
—
Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AUC(0-96hr): DM1 after Cycle 2
—
—
—
—
0.0561 h*µg/mL
Interval 0.0561 to 0.0561
0.0654 h*µg/mL
Interval 0.0484 to 0.077
0.0684 h*µg/mL
Interval 0.0684 to 0.0684
0.0688 h*µg/mL
Interval 0.0588 to 0.0865
—

SECONDARY outcome

Timeframe: AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)

Population: The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.

CL of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was determined.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=5 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=10 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 1
17.7 mL/hr
Interval 11.7 to 24.2
17.9 mL/hr
Interval 14.2 to 20.9
20.1 mL/hr
Interval 18.2 to 23.0
27.2 mL/hr
Interval 15.8 to 43.7
47.0 mL/hr
Interval 28.2 to 100.0
18.8 mL/hr
Interval 13.3 to 21.0
26.0 mL/hr
Interval 17.9 to 35.4
26.6 mL/hr
Interval 15.1 to 42.7
—
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 2
14.5 mL/hr
Interval 10.3 to 22.3
15.9 mL/hr
Interval 14.8 to 17.3
14.3 mL/hr
Interval 12.4 to 15.5
18.8 mL/hr
Interval 12.4 to 30.0
25.5 mL/hr
Interval 12.9 to 37.7
13.7 mL/hr
Interval 9.13 to 18.8
20.9 mL/hr
Interval 10.9 to 30.9
16.1 mL/hr
Interval 11.2 to 22.8
—
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 1
16.5 mL/hr
Interval 11.1 to 23.2
15.8 mL/hr
Interval 13.5 to 18.2
17.8 mL/hr
Interval 15.2 to 19.8
23.9 mL/hr
Interval 14.8 to 38.0
40.5 mL/hr
Interval 25.7 to 72.8
16.8 mL/hr
Interval 15.2 to 18.3
24.6 mL/hr
Interval 15.5 to 40.7
26.2 mL/hr
Interval 12.9 to 34.6
—
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 2
13.4 mL/hr
Interval 9.07 to 20.5
13.4 mL/hr
Interval 12.9 to 14.3
11.4 mL/hr
Interval 8.92 to 12.6
15.8 mL/hr
Interval 9.1 to 25.8
22.1 mL/hr
Interval 9.94 to 32.6
11.4 mL/hr
Interval 9.29 to 16.2
22.4 mL/hr
Interval 10.1 to 34.6
18.6 mL/hr
Interval 11.6 to 24.8
—
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
DM1 after Cycle 1
—
—
20800000 mL/hr
Interval 20400000.0 to 21300000.0
53300000 mL/hr
Interval 6310000.0 to 131000000.0
9310000 mL/hr
Interval 2190000.0 to 24300000.0
4360000 mL/hr
Interval 3180000.0 to 5790000.0
6100000 mL/hr
Interval 3740000.0 to 9350000.0
5620000 mL/hr
Interval 2160000.0 to 10600000.0
—
Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
DM1 after Cycle 2
—
18700000 mL/hr
Interval 18700000.0 to 18700000.0
69800000 mL/hr
Interval 13500000.0 to 173000000.0
11300000 mL/hr
Interval 5860000.0 to 21700000.0
5060000 mL/hr
Interval 2850000.0 to 7270000.0
2990000 mL/hr
Interval 2470000.0 to 3930000.0
5970000 mL/hr
Interval 3660000.0 to 8290000.0
3480000 mL/hr
Interval 2080000.0 to 4960000.0
—

SECONDARY outcome

Timeframe: AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)

Population: The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated. All participants included in the overall number of participants analyzed contributed data to this endpoint.

The t1/2,z of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=1 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=2 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=5 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=1 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=2 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=6 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 2
269 hours
Interval 250.0 to 277.0
255 hours
Interval 255.0 to 255.0
—
230 hours
Interval 211.0 to 249.0
351 hours
Interval 351.0 to 351.0
—
147 hours
Interval 147.0 to 147.0
199 hours
Interval 157.0 to 290.0
—
Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 1
217 hours
Interval 217.0 to 218.0
218 hours
Interval 191.0 to 284.0
278 hours
Interval 278.0 to 278.0
196 hours
Interval 174.0 to 219.0
139 hours
Interval 135.0 to 160.0
189 hours
Interval 189.0 to 189.0
195 hours
Interval 192.0 to 198.0
199 hours
Interval 158.0 to 217.0
—
Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
AMG 224 Conjugated Antibody after Cycle 2
201 hours
Interval 194.0 to 215.0
221 hours
Interval 193.0 to 249.0
—
189 hours
Interval 159.0 to 220.0
243 hours
Interval 155.0 to 300.0
164 hours
Interval 164.0 to 164.0
179 hours
Interval 179.0 to 179.0
241 hours
Interval 174.0 to 280.0
—
Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
Total Anti-BCMA Antibody after Cycle 1
234 hours
Interval 231.0 to 238.0
198 hours
Interval 198.0 to 198.0
—
242 hours
Interval 197.0 to 287.0
155 hours
Interval 51.0 to 189.0
238 hours
Interval 238.0 to 238.0
170 hours
Interval 170.0 to 170.0
194 hours
Interval 172.0 to 216.0
—
Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1
DM1 after Cycle 1
—
—
—
—
50.2 hours
Interval 50.2 to 50.2
52.1 hours
Interval 52.1 to 52.1
—
48.8 hours
Interval 48.8 to 48.8
—

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years

Population: Safety analysis set included all participants who received at least 1 dose of AMG 224.

BOR was the best observed post baseline disease response per IMWG-URC: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \< 200 mg/24-h. Minor Response (MR): 25-49% reduction of serum M-protein and 50-89% in 24-h urinary M-protein, exceeding 200 mg/24-h. Stable Disease (SD): Not meeting criteria for CR, VGPR, PR or Progressive Disease (PD). PD: ≥ 25% increase in serum or urine M-component, development of new or increased size of existing bone lesions or soft tissue plasmacytomas, hypercalcemia attributed to the plasma cell proliferative disorder.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
PR
1 Participants
0 Participants
0 Participants
0 Participants
2 Participants
0 Participants
1 Participants
1 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
sCR
0 Participants
0 Participants
0 Participants
1 Participants
0 Participants
1 Participants
0 Participants
0 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
CR
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
1 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
VGPR
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
1 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
MR
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
1 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
SD
2 Participants
1 Participants
1 Participants
2 Participants
1 Participants
2 Participants
1 Participants
2 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
Progressive disease
0 Participants
2 Participants
2 Participants
0 Participants
0 Participants
0 Participants
0 Participants
2 Participants
0 Participants
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
Unevaluable
0 Participants
0 Participants
0 Participants
0 Participants
3 Participants
3 Participants
3 Participants
2 Participants
1 Participants

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years

Population: The safety analysis set included all participants who received at least 1 dose of AMG 224.

TTP was the time from the first administration of AMG 224 to the first objective assessment of disease progression as per IMWG-URC or deaths or if applicable date of censoring. The median TTP was estimated using the Kaplan-Meier method

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Time To Progression (TTP) According to IMWG-URC
74.9 months
Interval 3.5 to
Too few events to estimate the upper 80% confidence interval (CI)
1.6 months
Interval 0.7 to
Too few events to estimate the upper 80% CI
1.4 months
Interval 0.8 to
Too few events to estimate the upper 80% CI
3.7 months
Interval 2.1 to
Too few events to estimate the upper 80% CI
14.0 months
Interval 11.6 to
Too few events to estimate the upper 80% CI
2.3 months
Interval 1.4 to 6.0
2.8 months
Interval 0.7 to
Too few events to estimate the upper 80% CI
7.2 months
Interval 0.7 to 12.3
4.4 months
Interval 0.3 to
Too few events to estimate the upper 80% CI

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years

Population: The safety analysis set included all participants who received at least 1 dose of AMG 224.

DOR was defined as the time between the date of the first observation indicating an objective response as PR (or better) through to the subsequent date of disease progression as classified by the IMWG-URC for Multiple Myeloma or death or where applicable date of censoring. The median DOR was estimated using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Duration of Response (DOR) According to IMWG-URC
63.1 months
Too few events to estimate the 80% CIs
NA months
No events therefore median and 80% CIs could not be estimated
NA months
No events therefore median and 80% CIs could not be estimated
60.8 months
Too few events to estimate the 80% CIs
9.1 months
Interval 8.1 to
Too few events to estimate the upper 80% CI
19.2 months
Too few events to estimate the 80% CIs
4.1 months
Too few events to estimate the 80% CIs
18.7 months
Interval 6.7 to
Too few events to estimate the upper 80% CI
7.7 months
Too few events to estimate the 80% CIs

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years

Population: Safety analysis set: all participants that are enrolled and received at least 1 dose of AMG 224.

MRD negative was defined as a tumor load of less than 1 clonal cell in 10\^5 normal cells (as determined by flow cytometry).

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Number of Participants With Conversion to Minimal Residual Disease (MRD)-Negativity
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 to up to the end of study visit; up to approximately 6 years

Population: The safety analysis set included all participants who received at least 1 dose of AMG 224.

The number of participants who tested positive for pre-existing binding antibodies prior to exposure to AMG 224 and who tested positive for anti-AMG 224 binding antibodies after dosing with AMG 224 are presented. Participants with transient post-baseline results were binding antibody positive post-baseline with a negative or no result at baseline and a negative result at the participant's last timepoint tested.

Outcome measures

Outcome measures
Measure
Dose Exploration: AMG 224 Dose A
n=3 Participants
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 Participants
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 Participants
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 Participants
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
n=6 Participants
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 Participants
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 Participants
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 Participants
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 Participants
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Number of Participants With Anti-AMG 224 Antibodies
Binding antibody positive at anytime
0 participants
0 participants
0 participants
0 participants
0 participants
2 participants
1 participants
1 participants
1 participants
Number of Participants With Anti-AMG 224 Antibodies
Binding antibody positive at/before baseline
0 participants
0 participants
0 participants
0 participants
0 participants
1 participants
0 participants
0 participants
1 participants
Number of Participants With Anti-AMG 224 Antibodies
Binding antibody positive post-baseline with a negative/no result at baseline
0 participants
0 participants
0 participants
0 participants
0 participants
1 participants
1 participants
1 participants
0 participants
Number of Participants With Anti-AMG 224 Antibodies
Binding antibody positive post-baseline with a negative/no result at baseline: Transient
0 participants
0 participants
0 participants
0 participants
0 participants
1 participants
0 participants
0 participants
0 participants

Adverse Events

Dose Exploration: AMG 224 Dose A

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose B

Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose C

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose D

Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose E

Serious events: 2 serious events
Other events: 5 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose F

Serious events: 2 serious events
Other events: 6 other events
Deaths: 0 deaths

Dose Exploration: AMG 224 Dose G

Serious events: 2 serious events
Other events: 5 other events
Deaths: 0 deaths

Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment

Serious events: 6 serious events
Other events: 7 other events
Deaths: 0 deaths

Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Dose Exploration: AMG 224 Dose A
n=3 participants at risk
Participants were administered AMG 224 Dose A as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 participants at risk
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 participants at risk
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 participants at risk
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks
Dose Exploration: AMG 224 Dose E
n=6 participants at risk
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 participants at risk
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 participants at risk
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 participants at risk
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 participants at risk
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Blood and lymphatic system disorders
Anaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Febrile neutropenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Neutropenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Plasma cell disorder
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Thrombocytopenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Atrial flutter
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Nausea
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Pyrexia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Hepatobiliary disorders
Cholecystitis acute
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Acute sinusitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Influenza
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Lower respiratory tract infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Parainfluenzae virus infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Pneumonia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Pneumonia pneumococcal
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Clavicle fracture
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Fall
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Femur fracture
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Infusion related reaction
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Platelet count decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Dehydration
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Failure to thrive
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Back pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Pathological fracture
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Facial paralysis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Left ventricular failure
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Septic shock
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Urinary tract infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Urinary tract infection bacterial
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Post procedural haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypervolaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Haematuria
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Hydronephrosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Haemoptysis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Skin haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.

Other adverse events

Other adverse events
Measure
Dose Exploration: AMG 224 Dose A
n=3 participants at risk
Participants were administered AMG 224 Dose A as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
n=3 participants at risk
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
n=3 participants at risk
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
n=3 participants at risk
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks
Dose Exploration: AMG 224 Dose E
n=6 participants at risk
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
n=6 participants at risk
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
n=5 participants at risk
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks
Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment
n=9 participants at risk
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment
n=2 participants at risk
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Blood and lymphatic system disorders
Splenic lesion
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Anaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
3/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
83.3%
5/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
60.0%
3/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Leukopenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Neutropenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Splenomegaly
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Thrombocytopenia
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
100.0%
3/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
83.3%
5/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
60.0%
3/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
6/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Blood and lymphatic system disorders
Thrombocytosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Palpitations
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Cardiac disorders
Tachycardia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Tinnitus
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Vertigo positional
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Conjunctival haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Diplopia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Dry eye
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Eye irritation
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Eye pruritus
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Lacrimation increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Ocular hyperaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Vision blurred
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Visual acuity reduced
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Visual impairment
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Eye disorders
Vitreous haemorrhage
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal discomfort
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal distension
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Abdominal pain upper
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Constipation
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Diarrhoea
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
3/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
44.4%
4/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Dry mouth
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Dysphagia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Flatulence
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Gingival bleeding
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Nausea
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
4/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
40.0%
2/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
3/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Oral disorder
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Stomatitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Toothache
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Vomiting
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Asthenia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Chest pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Chills
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Fatigue
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
100.0%
3/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
3/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
4/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
6/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Infusion site bruising
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Malaise
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Mucosal inflammation
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Oedema
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Oedema peripheral
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Pyrexia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Hepatobiliary disorders
Cholecystitis acute
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Beta haemolytic streptococcal infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Cellulitis
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Ear infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Folliculitis
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Gastroenteritis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Gastrointestinal candidiasis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Herpes ophthalmic
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Hordeolum
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Influenza
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Lower respiratory tract infection
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Nasopharyngitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Oral candidiasis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Otitis externa
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Respiratory tract infection
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Respiratory tract infection viral
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Rhinitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Upper respiratory tract infection
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Urinary tract infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Urinary tract infection staphylococcal
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Viral upper respiratory tract infection
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Contusion
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Foot fracture
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Skin abrasion
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Skin laceration
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Skin wound
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Stress fracture
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Injury, poisoning and procedural complications
Wound
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Activated partial thromboplastin time prolonged
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Alanine aminotransferase increased
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
3/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
40.0%
2/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
3/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Aspartate aminotransferase increased
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
4/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
40.0%
2/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
44.4%
4/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood alkaline phosphatase increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
60.0%
3/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
3/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood creatine increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood creatinine decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood creatinine increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood lactate dehydrogenase increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood potassium decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood urea increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Calcium ionised increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Coagulation time prolonged
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Gamma-glutamyltransferase increased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Lymphocyte count decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Platelet count decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Weight decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
White blood cell count decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Decreased appetite
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
3/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hyperalbuminaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypercalcaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
44.4%
4/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hyperglycaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
3/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypermagnesaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypernatraemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hyperuricaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypoalbuminaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypomagnesaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
40.0%
2/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Iron deficiency
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Arthralgia
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
55.6%
5/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Arthritis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Back pain
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Bone pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Groin pain
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Joint swelling
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscle spasms
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Muscular weakness
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Myalgia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
44.4%
4/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Pain in extremity
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Tendonitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Dizziness
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
2/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Headache
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
100.0%
2/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Hypoaesthesia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Memory impairment
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Neuropathy peripheral
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Paraesthesia
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Peripheral sensory neuropathy
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Tremor
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Agitation
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Depression
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Insomnia
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Restlessness
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Sleep disorder
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Stress
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Chromaturia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Haematuria
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Urinary incontinence
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Renal and urinary disorders
Urinary retention
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Cough
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
22.2%
2/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
3/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
100.0%
2/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Hiccups
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Nasal dryness
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Paranasal sinus discomfort
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Productive cough
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Alopecia
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Erythema
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Hyperhidrosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Night sweats
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Pruritus
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rash
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rash maculo-papular
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Rosacea
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Skin induration
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Skin lesion
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Surgical and medical procedures
Cholecystectomy
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Surgical and medical procedures
Skin neoplasm excision
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Flushing
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Hot flush
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Hypertension
66.7%
2/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Vascular disorders
Hypotension
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
16.7%
1/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Congenital, familial and genetic disorders
Phimosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Ear and labyrinth disorders
Ear haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Gastrooesophageal reflux disease
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Haemorrhoidal haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Mouth haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Proctalgia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Gastrointestinal disorders
Rectal haemorrhage
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
General disorders
Influenza like illness
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Hepatobiliary disorders
Hepatic steatosis
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Metapneumovirus infection
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Sinusitis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Infections and infestations
Skin infection
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Investigations
Blood bilirubin increased
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Metabolism and nutrition disorders
Hypokalaemia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acrochordon
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Dizziness postural
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
20.0%
1/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Nervous system disorders
Taste disorder
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Product Issues
Product after taste
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Psychiatric disorders
Confusional state
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dysphonia
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
11.1%
1/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Actinic keratosis
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
33.3%
1/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Skin and subcutaneous tissue disorders
Spider naevus
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
Surgical and medical procedures
Sinus operation
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/3 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/6 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/5 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
0.00%
0/9 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
50.0%
1/2 • All-cause mortality was collected from enrollment to the end of study visit, up to approximately 6 years. Treatment-emergent adverse events were collected from the first administration of AMG 224 up to 37 days after the last dose of investigational product (median treatment duration was 9 weeks).
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Results disclosure agreements

  • Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
  • Publication restrictions are in place

Restriction type: OTHER